{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:11:02Z","timestamp":1763017862066,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clml.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T20:25:29Z","timestamp":1518639929000},"page":"272-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Sigal","family":"Grisariu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Y.","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuven","family":"Or","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.008_bib1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2009-0162","article-title":"Controversies in the treatment of lymphoma with autologous transplantation","volume":"14","author":"Moskowitz","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2018.02.008_bib2","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.3324\/haematol.2014.119214","article-title":"Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway","volume":"100","author":"Smeland","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.008_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.008_bib4","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","article-title":"Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"17","author":"Friedberg","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.008_bib5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.008_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","article-title":"BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.008_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.008_bib8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bmt.1705838","article-title":"The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation","volume":"40","author":"Abdul-Hai","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.008_bib9","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.3109\/10428194.2013.782608","article-title":"Autologous transplant in multiple myeloma with an augmented conditioning protocol","volume":"54","author":"Abu Zaid","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.008_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/bmt.2015.273","article-title":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT","volume":"51","author":"Sellner","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.008_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.008_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10238-011-0157-2","article-title":"High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma","volume":"12","author":"Falzetti","year":"2012","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.clml.2018.02.008_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","article-title":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma","volume":"34","author":"Wang","year":"2004","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.008_bib14","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","article-title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning","volume":"57","author":"Isidori","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.008_bib15","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","article-title":"Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation","volume":"47","author":"Puig","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.008_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bmt.2017.205","article-title":"Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma","volume":"53","author":"Joffe","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.008_bib17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3109\/10428194.2011.645208","article-title":"Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant","volume":"53","author":"Lane","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.008_bib18","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.15.5507","article-title":"Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma","volume":"26","author":"Goodman","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.008_bib19","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","volume":"22","author":"Lenz","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.008_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","article-title":"Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma","volume":"13","author":"William","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.02.008_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13234","article-title":"Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study","volume":"168","author":"Kirschey","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.008_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/17474086.2015.1044432","article-title":"Brentuximab vedotin for the treatment of Hodgkin's lymphoma","volume":"8","author":"Pham","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2018.02.008_bib23","first-page":"1039","article-title":"Advancement in high dose therapy and autologous stem cell rescue in lymphoma","volume":"7","author":"Isidori","year":"2015","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.clml.2018.02.008_bib24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.bmt.1705744","article-title":"Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?","volume":"40","author":"Fernandez","year":"2007","journal-title":"Bone Marrow Transpl"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017318499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017318499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:22Z","timestamp":1761870622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017318499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S2152265017318499"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}